M. Intra, N. Rotmensz, P. Veronesi, M. Colleoni, S. Iodice, G. Paganelli, et al., “Sentinel Node Biopsy Is Not a Standard Procedure in Ductal Carcinoma in Situ of the Breast: Experience of the European Institute of Oncology on 854 Patients in 10 Years,” Annals of Surgery, Vol. 247, No. 2, 2008, pp. 315-319. doi:10.1097/SLA.0b013e31815b446b

has been cited by the following article:

• TITLE: Axillary Recurrences after Sentinel Node Surgery—Results over Ten Years in a University Hospital

  AUTHORS: Helle Eilertsen, Ellen Schlichting, Marianne Efskind Harr, Daehoon Park, Torill Sauer, Siri Larønningen, Rolf Kaaresen

  KEYWORDS: Breast Cancer; Ductal Carcinoma in Situ; Sentinel Node; Non-Sentinel Metastasis; Axillary Recurrence

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.5A, November 2, 2012

  ABSTRACT: Background: Sentinel node biopsy (SNB) was introduced at Ullevaal University Hospital in 2000. This article presents results from the first ten years use of the method. Material and Methods: A prospective registration of 2762 patients was made from 2000 through 2009. Results: The median follow-up time was 51 months. The overall detection rate was 93%. 36% of the patients with positive SNs had non-sentinel metastases. These were significantly associated with a macrometastatic SN and a primary tumour>20 mm. 18% of patients with sentinel metastasis≤2 mm had non-sentinel metastases. 14 patients with negative SN (0.7%) developed axillary recurrence. 32% with a preoperative diagnosis of ductal carcinoma in situ (DCIS) were upstaged to infiltrating carcinoma on final histology. None of the patients with pure DCIS had positive SNs. Conclusion: Few late events (0.7%) in SN negative axillas demonstrate the safety of the technique.